Patients whose atrial fibrillation lasts longer than seven days and who do not respond well to drug therapy are now eligible ...

The US Food and Drug Administration (FDA) has approved Boston Scientific’s expanded instructions for use (IFU) labelling of ...

Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...

Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, ...

Marlborough: Boston Scientific Corporation has announced that the company has received approval from the U.S. Food and Drug ...

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the ...

Boston Scientific (NYSE: BSX) announced that the FDA approved an expansion to the label of its Farapulse pulsed field ...

Boston Scientific Corp. gained a second U.S. FDA approval for its Farapulse pulsed field ablation catheter, expanding its use into drug-refractory, symptomatic persistent atrial fibrillation (AF) in ...

"These positive study results are an important step forward in the continued innovation of the proven FARAPULSE PFA System and our broader portfolio of products that treat AF," said Brad Sutton, M ...

Trial achieves positive results in the treatment of persistent atrial fibrillation MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today ...

MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ...